Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma

Hideaki MATSUMURA,† Eiichi ISHIKAWA,† Masahide MATSUDA,† Noriaki SAKAMOTO,† Hiroyoshi AKUTSU,† Shingo TAKANO,† and Akira MATSUMURA†

†Department of Neurosurgery, University of Tsukuba, Tsukuba, Ibaraki, Japan

Abstract

A 43-year-old man was operated on for right frontal oligoastrocytoma. 14 years after the surgery, magnetic resonance imaging and positron emission tomography revealed a new lesion near the surgical cavity. He underwent gross total resection of the lesion and implantation of bis-chloroethylnitrosourea (BCNU) wafers after intraoperative pathological diagnosis of recurrent high-grade glioma. A few days after the operation, the level of consciousness gradually worsened and left hemiparesis developed. A computed tomography scan revealed a cyst remote to the surgical cavity which did not exist 3 days prior. We performed anterior cyst wall fenestration and removed all wafers. The characteristic pathological finding at the wafer implantation site was severe inflammation within and around small vessels. This inflammatory reaction was not seen on the surface of the brain parenchyma. After surgery and rehabilitation, the patient's Karnofsky Performance Status stabilized to a pre-incident score of 90 and he returned to work. The exact pathophysiological mechanism of the cyst was not clear, but check-valve and/or osmotic gradient mechanisms related to BCNU wafer implantation could have contributed to this phenomenon. As remote cyst development happened a week after surgery, surgeons should be aware of such a rare condition when implanting wafers as consciousness impairment and hemiparesis may occur. Close radiological follow-up is therefore necessary.

Key words: BCNU wafers, carmustine wafers, cyst formation, symptomatic remote cyst, malignant glioma

Introduction

bis-Chloroethylnitrosourea (BCNU, carmustine) wafer implantation is a common adjuvant therapy for malignant glioma.1,2 After tumor removal, the wafers are placed on the walls of the resection cavity and BCNU is slowly released over a period of 2 weeks. A phase III, randomized, controlled trial demonstrated a significant improvement in the median overall survival time of 120 patients by 2.3–13.9 months.1 Some complications of BCNU wafer implantation, such as edema formation, hydrocephalus, and wound site complications, are known and the formation of tumor bed cysts is also considered as a complication.3 This is because BCNU wafers sometimes form a space-occupying cyst in and/or around the resection cavity which forms a so-called tumor bed cyst and several previous reports describe this phenomenon.4,5 However, remote cyst formation after BCNU implantation on the cavity walls has not been described previously. Herein, we report a first case of remote cyst formation causing hemiparesis and consciousness impairment after BCNU wafer implantation. We also discuss pathological findings of the brain parenchyma around wafers and the cyst wall.

Case Report

A 43-year-old Japanese man was diagnosed with a right frontal brain tumor and underwent gross total resection. After pathological diagnosis of oligoastrocytoma by the 2007 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) criteria, he subsequently underwent radiation therapy (60.4 Gy) with two rounds of vincristine (2 mg) and nimustine (140 mg). After completing the chemoradiotherapy, the patient was discharged and visited a regional hospital regularly for follow-ups. He did not develop any neurological sequelae other than occasional episodes of epilepsy [Karnofsky Performance Status (KPS) was 90].
14 years after the first operation, in spite of being asymptomatic, $T_2$-weighted magnetic resonance imaging (MRI) revealed a new high-intensity area around the surgical cavity (Fig. 1a) and positron emission tomography using $^{11}$C-methionine showed a high integration degree in that area (Fig. 1b). The lesion was diagnosed as a tumor recurrence and tumorectomy/BCNU wafer implantation on the surgical cavity wall after intraoperative pathological diagnosis of recurrent high-grade glioma (HGG) was performed uneventfully as follows: The previous operation (14 years prior) had fused the dura mater to the cerebral surface and sharp dissection was needed to detach it. The lateral ventricle was opened during tumor resection and we reconstructed the ventricle wall with a hemostatic gelatin sponge and fibrin glue before implanting 6 wafers on the resected cavity (Figs. 2a and 2b). MRI revealed no residual tumor and no adverse events, except for a small cerebral infarction (Fig. 1f, white arrow), occurred the day after surgery (Figs. 1c–1f).

There were no new neurological symptoms soon after surgery, however, the level of consciousness gradually worsened and left hemiparesis developed gradually over 4 days after surgery. Although no new lesions appeared on computed tomography (CT) scans 4 days post-surgery (Fig. 3a), on the 7th post-surgical day CT scans revealed a cyst with a maximal diameter of 37 mm, located away from the surgical cavity, and compressing the right primary motor area (Fig. 3b). The intensity of the fluid in the cyst was almost the same as the cerebrospinal fluid (CSF) (Figs. 3c–3f), however, fluid-attenuated inversion recovery (FLAIR) images showed the different intensities between surgical cavity and the cyst. Though the signal intensity was relative value, the mean of tumor resected cavity, contralateral lateral ventricle, and cyst were 194, 153, and 497 respectively under the same imaging parameters (Figs. 4a–4c). The surgical removal of the wafers and fenestration of the anterior wall of the cyst was then performed as follows: The exposed cyst

![Image](image-url)

**Fig. 1** Perioperative neuroimaging. A $T_2$-weighted magnetic resonance imaging (MRI) (a) and $^{11}$C-methionine positron emission tomography (b) indicating the recurrence of the tumor next to the previous surgical cavity in the right frontal lobe. $T_2$-weighted MRI on the day after surgery showing the postoperative cavity after recurrent tumor resection with open anterior horn of the right lateral ventricle (c). BCNU wafers placed on the surface of the cavity after closing the lateral ventricle with an absorbable compressed gelatin sponge (d and e). The diffusion-weighted MRI shows a small high intensity spot-like area in the right frontal lobe (f, white arrow head), the small cerebral ischemia area located apart from the surgical cavity.
Fig. 2 Operative findings of the tumor resection. Operative findings showing the tumor resected cavity before (a) and after (b) occlusion of the ventricle and implantation of 6 wafers. The upper right side indicates the frontal cranial base and the upper left indicates the medial side. The asterisk showing the lateral ventricle reconstructed by the gelatin sponge.

Fig. 3 Consecutive postoperative neuroimaging. Computed tomography (CT) scan on 4th day after the surgery shows no cyst formation (a). CT and MRI on the 7th day after the surgery reveals remote cyst formation (b–f). The cyst is apart from the resection cavity on sagittal T₂-weighted MRI (d). No abscess evidence on diffusion-weighted images (e). Signal intensity of liquid content of the cyst is almost the same as the cerebrospinal fluid (CSF) on T₂-weighted MRI (f).

was visible on the brain surface immediately after reopening the sutured dura mater (Figs. 5a and 5b) and was located away from the initial surgical cavity with a distance of one to two gyri between them. We punctured the cavity with the dissector and transparent fluid resembling CSF effused with moderate pressure (Figs. 5b and 5d). We removed the anterior wall of the cyst and connected the cyst directly to the tumor-resected cavity. We also removed the BCNU wafers and opened the lateral ventricle previously occluded by the hemostatic gelatin sponge (Fig. 5e). After fenestration, consciousness level and left hemiparesis gradually improved while subsequent CT revealed a decrease in cystic portion (Figs. 5c and 5f). Pathological analysis of the cyst wall revealed no inflammatory or tumor cells (Figs. 6a and 6b) but there was an inflammatory reaction at the attachment site of the BCNU wafers (Fig. 7a). These inflammatory cell infiltrations were predominant within and around small vessels which were a short distance from the BCNU wafers (Figs. 7a and 7b). After 3 months of rehabilitation, the patient returned to work with a KPS of 90 as before the operation. The final pathological diagnosis was recurrent HGG compatible with anaplastic oligodendroglioma (NOS in the 2016 WHO classification of CNS tumors)
Symptomatic Remote Cyst after BCNU Wafer Implantation

Fig. 4 Intensity difference of tumor resected cavity, lateral ventricle, and cyst on fluid-attenuated inversion recovery (FLAIR) images. FLAIR images taken under the same imaging parameters show the different intensities in the tumor resected cavity (a), a contralateral lateral ventricle as a control value of CSF (b), and the cyst (c). Each column (a–c) shows same coronal FLAIR image (upper, original images; lower, magnified images with intensity values of randomly selected three points).

Fig. 5 Operative findings of the cyst fenestration. Operative findings showing the cyst before opening (a and b) and after opening (d). The cyst was easily punctured (b and d). The posterior wall of the tumor resected cavity and the anterior wall of the cyst are partially removed, and the cyst and the tumor resected cavity are connected to each other (e). The left side of the images corresponds to the frontal cranial base, and the lower side of the images corresponds to the medial side of the head. CT scans the day after cyst fenestration show the disappearance of the cyst (c and f).
and the patient received adjuvant temozolomide. There is no evidence of recurrence at over 26 months after the first operation for recurrent HGG.

**Discussion**

In the present case, the symptomatic remote cyst formation occurred after BCNU wafer implantation. BCNU wafers have been widely used for glioma adjuvant therapy after being approved by the United States Food and Drug Administration in 1997. Although considered efficacious as an antineoplastic, BCNU adverse events such as wound complications, CSF leakage, local edema, seizures, and hydrocephalus have been reported. Tumor bed cysts have also been reported previously as a space-occupying cyst in the resection cavity. However, to the best of our knowledge, this is the first case of a symptomatic remote cyst associated with BCNU wafers.

Although it was not obvious on CT scans up to 4 days post-surgery, we eventually detected the remote cyst on the 7th day. Judging from such radiological findings, the formation of the cyst seems to have occurred after the 4th day. Based on the cystic fluid examination and pathological findings of the cyst wall, abscess or hemorrhage were not observed and could not be related to or cause cyst formation. Similarly, the tumor recurrence could not be directly related to cyst formation as the cyst was characterized by acute formation and no tumor cells in the cyst wall. Therefore, the detailed pathophysiology of this remote cystic formation remains obscure. In our case, the lateral ventricle was opened and reconstructed with a hemostatic gelatin sponge. A previous report about a tumor bed cyst identified a statistically negative correlation between tumor bed cyst enlargement and ventricular opening, since the reactive fluid draining into the CSF limits the enlargement of the tumor bed cyst in case of...
Symptomatic Remote Cyst after BCNU Wafer Implantation

In conclusion, we experienced a symptomatic remote cyst formation after BCNU wafer implantation for recurrent HGG. The cyst was formed within several days in the postoperative period. We hypothesized that a check-valve or osmotic gradient effect related to different BCNU concentrations was one of the mechanisms of the cyst formation. This indicates that any imaging anomalies, especially those indicative of ischemia, should be monitored after wafer implants, even up to a week after an uneventful surgery.

Acknowledgments

We thank Dr. Alexander Zaboronok of the University of Tsukuba Faculty of Medicine, Department of Neurosurgery, for professional revision and Dr. Bryan J. Mathis of the University of Tsukuba Medical English Communication Center for native English revision.

Conflicts of Interest Disclosure

The authors declare that they have no financial or other conflicts of interest in relation to this research and its publication.

References

1) Westphal M, Hilt DC, Bortey E, et al.: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5: 79–88, 2003
2) Brem H, Piantadosi S, Burger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345: 1008–1012, 1995
3) Aoki T, Nishikawa R, Sugiyama K, et al.: A multicenter phase I/II study of the BCNU implant (Gliadel® Wafer) for Japanese patients with malignant gliomas. Neurol Med Chir (Tokyo) 54: 290–301, 2014
4) Hasegawa Y, Iuchi T, Sakaida T, Yokoi S, Kawasaki K: The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. J Clin Neurosci 31: 67–71, 2016
5) Dörner L, Ulmer S, Rohr A, Mehdorn HM, Nabavi A: Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation—incidence, therapeutic strategies, and outcome. J Clin Neurosci 18: 347–351, 2011
6) Sampath P, Brem H: Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 5: 130–137, 1998

Neurol Med Chir (Tokyo) 58, June, 2018
7) Ishikawa E, Yamamoto T: [Intraoperative BCNU wafer implantation for high-grade glioma—a questionnaire targeting Japanese neurosurgeons]. Gan To Kagaku Ryoho 43: 603–607, 2016 (Japanese)

8) Ishikawa E, Yamamoto T, Satomi K, et al.: Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind. Brain Tumor Pathol 31: 156–161, 2014

9) Masuda Y, Ishikawa E, Yamamoto T, et al.: Early postoperative expansion of parenchymal high-intensity areas on T2-weighted imaging predicts delayed cerebral edema caused by carmustine wafer implantation in patients with high-grade glioma. Magn Reson Med Sci 15: 299–307, 2016

10) Ohue S, Kohno S, Inoue A, et al.: Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence. J Neurooncol 126: 119–126, 2016

11) Ohue S: [Using BCNU Wafers in the treatment of Malignant Gliomas]. Jpn J Neurosurg (Tokyo) 25: 882–888, 2016 (Japanese)

12) Mena H, Cadavid D, Rushing EJ: Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathol 108: 524–530, 2004

Address reprint requests to: Eiichi Ishikawa, Department of Neurosurgery, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
e-mail: e-ishikawa@md.tsukuba.ac.jp